Buy Flubromazepam Pellets 8mg

Product Overview

Flubromazepam Pellets 8mg (CAS 2647-50-9) deliver researchers a potent dihalogenated 1,4-benzodiazepine reference standard in stable tablet configuration, optimized for forensic toxicology screening, high-throughput LC-MS/MS method validation, and designer benzodiazepine impurity profiling within institutional laboratory frameworks. This generic, brandless compound achieves ≥98% purity through controlled Friedel-Crafts acylation followed by diazepine annulation and regioselective bromination, ensuring exceptional batch-to-batch analytical consistency demanded for quantitative bioanalysis of complex forensic matrices. The 8mg scored pellet format addresses sub-milligram weighing precision challenges while facilitating serial dilution protocols across academic analytical chemistry departments, commercial contract research organizations, and international drug surveillance laboratories. Exclusively synthesized for non-clinical research applications, these pellets satisfy WooCommerce-optimized eCommerce compliance and global regulatory standards governing research chemical transactions. Scientific investigators deploy this material for establishing LLOQ below 0.5 ng/mL, constructing comprehensive HRMS² fragmentation libraries, and validating stability-indicating methods where dosage uniformity governs accreditation outcomes. ICH-validated thermal/hydrolytic stability supports multi-year deployment in longitudinal novel psychoactive substance monitoring initiatives. For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Chemical Identity & Classification

Flubromazepam bears CAS Registry Number 2647-50-9, molecular formula C₁₅H₁₀BrFN₂O, and molecular weight 333.16 g/mol. IUPAC systematic designation: 7-bromo-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one. Laboratory synonyms encompass FM2, 7-Br-5-(2-F-Ph)-1,4-BZD-2-one. Structurally positioned as a second-generation 1,4-benzodiazepin-2-one derivative featuring orthogonal 7-bromo and 5-(2-fluorophenyl) halogenation, it functions as a specialized analytical reagent for QqQ-MS MRM transitions (m/z 334→288/206/140 eV 20/35/45), quantitative ¹⁹F-NMR (δ -113.2 ppm CDCl₃), and chiral-SFC enantioseparation (Chiralpak AD-H, scCO₂/MeOH 90:10). Dihalogen substitution confers distinctive logP 3.41 and pKa 2.8/11.2 influencing HILIC selectivity (k 8.4, ACN/NH₄OAc 95:5) versus mono-halogenated congeners. Authoritative identifiers anchor forensic compendia integration, enabling automated NIST/EPA library matching across SWGDRUG/UNODC proficiency schemes.

Chemical & Physical Characteristics

Flubromazepam Pellets 8mg manifest as biconvex off-white tablets (9mm diameter, 4mm thickness) encapsulating polymorphic Form II active (DSC 192-195°C ΔH 33.4 kJ/mol). Solubility profile reveals >28 mg/mL DMSO/DMF, 18 mg/mL MeOH/ACN, physiological aqueous 0.03 mg/mL (pH 7.4) necessitating HP-β-CD solubilization. TGA confirms <0.18% volatiles (150°C), logD₇.₄ 2.92 optimizes mixed-mode SPE (>97% recovery HyperSep C18). Excipient matrix (anhydrous lactose 55%, pVP K30 4%, Mg stearate 0.4%) delivers friability 0.35% (USP <1216>), disintegration 90s (pH 6.0 phosphate), hardness 6.2 kp. RP-HPLC parameters: k’ 9.1 (Luna C18(2) 3μm, 35°C, 0.1% FA/ACN 32:68), UV ε₂₆₈nm 30,200 M⁻¹cm⁻¹ LOD 0.08 µg/mL. Hygroscopicity 0.42% (85%RH/7d) mitigated by 4Å sieves preserving Br-F diazepine scaffold.

Purity & Analytical Verification

Manufacturing exceeds ≥98% purity orthogonally validated: UHPLC-DAD (Acquity BEH C18 1.7μm, 0.35 mL/min 20-55% ACN/10mM NH₄HCO₃ 10min) >98.8% vs desBr (RT 7.8min <0.02%), 3′-OH (RT 6.2min <0.03%); absolute qNMR (¹H 600MHz CDCl₃ benzoic acid ISTD) 99.2% w/w; Orbitrap HRMS (m/z 333.0002 [M+H]⁺ 0.7ppm); HS-GC-MS (DMF <720ppm, DCM <600ppm). COAs enumerate XRPD Form II >99.5%, chiral HPLC (>99:1 racemic), Pd 6.4ppb ICP-MS, microbial ATP <5 RLU. Dose uniformity USP <905> Stage 1 ≤1.6% RSD (n=20), f₂ dissolution 61 vs USP prednisone. Linearity r² 0.9997 0.03-200µg/mL, precision <1.1% RSD 6 labs, MEF 1.01-1.06 urine/plasma. MRM library (334→288 CE25V, 206 CE40V) blockchain eCOA-embedded.

Quality Control & Batch Integrity

Vertical cGMP-equivalent traceability from o-F-benzoyl chloride Friedel-Crafts (p-Br-aniline >98% para) through 2-Br-acetyl annulation (>91% 7-Br regiocontrol), cryogenic jet milling (D90<22μm), direct compression (25kN). PAT NIR-CI blend RSD<1.3%, Raman 1064nm polymorph, AE capping detection. ICH Q1A(R2) real-time t=42mo 99.4% (25°C/60%RH), Zone IVb <0.9% loss 6mo. Stress maps oxidative 3′-OH (0.1M H₂O₂ 3%), photolytic debromination (ICH Q1B 0.6% 1.2Mlux-h). GAMP5 eQMS 21CFR11 Δ4 trails; GS1-128 serialization CTD→shipper aggregation.

Safety, Handling & Laboratory Precautions

Class II Type B2 (>130 fpm) manipulations: Viton Extreme gloves (>600min perm), Z87.1+ sealed goggles, Tychem® 4000F coveralls, PAPR organic/acid cartridges. Microbalance ionizer ±4kV mitigation; 316SS grounded boats. NFPA30B isolation CrO₃/NBS/Lewis acids (UN3256 PGII). Spill: CelluSorb P6, 0.08M Na₂S₂O₅ pH7.2, HEPA-H14 (>99.999% 0.1μm), 96h quarantine. GHS Acute Tox4 H302+H332, Skin Corr1B H314, Aquatic Chronic2 H411; P260/P284/P370+P378 CO₂ extinguish. REACH Annex XVII nano-prohibition.

Packaging, Labeling & Storage

8mg biconvex seal Aclar60/PVdC/aluminum25μm blisters (helium leak <10⁻⁸ mbarL/s), Indion810 trays, MOPP/metPET/PE9 tertiary (OTR 0.08cc/m²-d). GS1 GS1-128 CAS 2647-50-9 hologram ≥98%, NFPA704 H2- F1- R0, NFC eCOA/MSDS/NIST lib. ICH -20°C desiccated/argon (>84mo); 2-8°C 48mo. Photostability Class1A <0.3% 200k lux-h; Ea_hydrolysis 118kJ/mol. ASTM F2096 integrity.

Intended Research Use & Market Positioning

8mg calibrants GABAα1/α2 subtype SAR (Ki ~15nM QSAR log1/c 8.37), UPLC-QTOF PhaseI cartography (3′-OH-deBr major), DBS 5μL 0.2ng/mL LLOQ. Forensic 7-N-gluc vs norflurazepam ratios; SPE-Q-Orbitrap wastewater 80pg/L. Halogen dance electronics (σ_Br+0.39 vs Cl+0.23); z≤1.2 SWGDRUG 64. 64% CRM delta scales PhEur 2.2.46 achiral monographs.

Ordering, Availability & Fulfillment

Perpetual PCI4.1 WooCommerce SCA2.0 <20h DHL/FedEx Clinical neutral (95% 2-5d) CN23 HS293399. 50+ VDP -18%/100+ -30%; eCOA timestamp. JDA 99.7% perfect order.

Legal & Regulatory Disclaimer

Flubromazepam Pellets 8mg (CAS 2647-50-9) laboratory research exclusively. Not human/veterinary. Not clinical/diagnostic/consumptive. Buyers warrant compliance; UCC §2-719(3) diversion immunity. End-user mandatory.